<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584231</url>
  </required_header>
  <id_info>
    <org_study_id>EC/2015/0616</org_study_id>
    <secondary_id>2014-005200-13</secondary_id>
    <nct_id>NCT02584231</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from nocturnal enuresis (starting from the age of 5 till adulthood) are
      all treated with the same dose of desmopressin, i.e. 120mcg once daily. In treatment
      resistant enuresis, this dose is doubled: those patients take 240mcg once daily. A pilot
      study performed at our department showed a correlation between weight and plasma
      concentration when a fixed dose of desmopressin oral lyophilisate formulation was given to
      the pediatric patient (older than 6 years). This study will investigate the pharmacokinetics
      (PK) and pharmacodynamics (PD) of desmopressin in young children, less than 8 years old.
      Additionally, the efficacy of desmopressin oral lyophilisate formulation in urinary
      concentration testing will be evaluated
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2015</start_date>
  <completion_date type="Actual">February 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 19, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Desmopressine concentrations</measure>
    <time_frame>24 hours</time_frame>
    <description>The assessed pharmacokinetic parameters are desmopressine concentrations at timepoints 0, 1/4, 1/2, 1, 2, 3, 5, 6 and 7h.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - urinary volume.</measure>
    <time_frame>24 hours</time_frame>
    <description>PD of desmopressin in children with nocturnal enuresis that is resistant to treatment with desmopressin tablet. First PD parameter is antidiuretic effect. This is urinary volume per hour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy - osmolality in urine.</measure>
    <time_frame>24 hours</time_frame>
    <description>PD of desmopressin in children with nocturnal enuresis that is resistant to treatment with desmopressin tablet. Second PD parameter is urinary concentration capacity. This is osmolality in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary concentration test</measure>
    <time_frame>24 hours</time_frame>
    <description>Evaluation of the oral lyophilisate formulation of desmopressin for the urinary concentration test. Assessed parameter is urinary concentration capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of desmopressin in children as assessed by registration of adverse events.</measure>
    <time_frame>24 hours</time_frame>
    <description>Registration of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of desmopressin in children as assessed by the measurement of natremia.</measure>
    <time_frame>24 hours</time_frame>
    <description>Measurement of natremia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Monosymptomatic Nocturnal Enuresis</condition>
  <arm_group>
    <arm_group_label>Patients needing an urinary concentration test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who need a urinary concentration test because of uro- or nephropathy (age: 6 months - 8 year)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients suffering from treatment resistant nocturnal enuresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients suffering from treatment resistant nocturnal enuresis (age: 5 - 8 year)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desmopressin</intervention_name>
    <description>One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: &gt;6 months and &lt; 2years: 60µg; ≥2 years and &lt;4 years: 120µg PO and ≥4 years and &lt;8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety</description>
    <arm_group_label>Patients needing an urinary concentration test</arm_group_label>
    <arm_group_label>Patients suffering from treatment resistant nocturnal enuresis</arm_group_label>
    <other_name>dDAVP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with an uro- and/or nephropathy who need an urinary concentration test OR
             Children with monosymptomatic nocturnal enuresis (based on nocturnal polyuria) with
             treatment failure on desmopressin tablet

          -  Otherwise healthy children (on medical history and physical examination)

          -  Parents or legal guardian of the child signed the informed consent form

          -  Age: between 6 months and 8 years

          -  Minimum weight: 8 kg

        Exclusion Criteria:

          -  Diabetes insipidus

          -  Renal failure (eGFR&lt;60ml/min/1,73m²)

          -  Current urinary tract infection

          -  Syndrome of inappropriate antidiuretic hormone secretion

          -  Heart failure

          -  Clinical significant medical conditions (renal, hepatic, gastro-intestinal, pulmonary,
             cardiac, endocrinologic) that might interfere with the clinical endpoints

          -  Sensitivity to desmopressin or excipients of the oral lyophilisate formulation

          -  Use of antibiotics, diuretics or other drugs that can influence diuresis (tricyclic
             antidepressants, chlorpropamide, oxcarbazepine, selective serotonin reuptake
             inhibitors, chlorpromazine and carbamazepine).

          -  Use of drugs that influence intestinal motility (such as loperamide)

          -  Anomalies of the mouth that might interfere with the intake / absorption of the
             medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ghent University Hospital - Department of Paediatric Nephrology</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>February 4, 2019</last_update_submitted>
  <last_update_submitted_qc>February 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Ghent</investigator_affiliation>
    <investigator_full_name>Pediatrie</investigator_full_name>
    <investigator_title>Prof Johan Vande Walle</investigator_title>
  </responsible_party>
  <keyword>Desmopressin</keyword>
  <keyword>Paediatrics</keyword>
  <keyword>urinary concentration test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Nocturnal Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

